KH7 (KH-7) is a novel and potent Inhibitor of Sac (soluble adenylyl cyclase) with IC50s of 3-10 μM against both recombinant purified human sACt protein and heterologously expressed sACt in cellular assays. It is also a cAMP inhibitor.
Physicochemical Properties
| Molecular Formula | C17H15BRN4O2S |
| Molecular Weight | 419.297 |
| Exact Mass | 418.009 |
| Elemental Analysis | C, 48.70; H, 3.61; Br, 19.06; N, 13.36; O, 7.63; S, 7.65 |
| CAS # | 330676-02-3 |
| PubChem CID | 135496218 |
| Appearance | White to light yellow solid powder |
| Density | 1.6±0.1 g/cm3 |
| Index of Refraction | 1.716 |
| LogP | 6.01 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 5 |
| Heavy Atom Count | 25 |
| Complexity | 495 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | CC(C(N/N=C/C1=C(O)C=CC(Br)=C1)=O)SC1NC2=C(C=CC=C2)N=1 |
| InChi Key | WILMXUAKQKGGCC-DJKKODMXSA-N |
| InChi Code | InChI=1S/C17H15BrN4O2S/c1-10(25-17-20-13-4-2-3-5-14(13)21-17)16(24)22-19-9-11-8-12(18)6-7-15(11)23/h2-10,23H,1H3,(H,20,21)(H,22,24)/b19-9+ |
| Chemical Name | 2-(1H-benzimidazol-2-ylsulfanyl)-N-[(E)-(5-bromo-2-hydroxyphenyl)methylideneamino]propanamide |
| Synonyms | KH-7; KH7; KH 7 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | recombinant sACt ( IC50 = 3-10 μM ) |
| ln Vitro | KH7 (10 μM) inhibits this increase in cAMP caused by capture energy. In beer, KH7 significantly reduces basal cAMP accumulation, regardless of incubation medium, at higher concentrations (50 μM), 5 to 10 times higher than its IC50 and still selective against tmAC and sAC [1]. KH7 inhibits the synthesis of CaSF [2]. Myocytes exhibit a 20% negative inotropic effect (NIE) when KH7 is present, suggesting a role for sAC in the development of basal myocardial contractility [2]. |
| References |
[1]. The "soluble" adenylyl cyclase in sperm mediates multiple signaling events required for fertilization. Dev Cell. 2005 Aug;9(2):249-59. [2]. Maresin Conjugates in Tissue Regeneration 1 improves alveolar fluid clearance by up-regulating alveolar ENaC, Na, K-ATPase in lipopolysaccharide-induced acute lung injury. 4.658J Cell Mol Med. 2020 Mar 11. |
Solubility Data
| Solubility (In Vitro) | DMSO: ~250 mg/mL (~596.2 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (5.96 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.96 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (4.96 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3849 mL | 11.9246 mL | 23.8493 mL | |
| 5 mM | 0.4770 mL | 2.3849 mL | 4.7699 mL | |
| 10 mM | 0.2385 mL | 1.1925 mL | 2.3849 mL |